Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

PHASE3RecruitingINTERVENTIONAL
Enrollment

870

Participants

Timeline

Start Date

August 19, 2013

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions
Gastric Cancer
Interventions
DRUG

capecitabine

capecitabine 1250 milligram (mg) / m² po bid (D1-14)

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Ulsan University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Seoul National University Boramae Hospital

OTHER

collaborator

Ajou University School of Medicine

OTHER

collaborator

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

OTHER

collaborator

Hallym University Medical Center

OTHER

collaborator

Inje University Haeundae Paik Hospital

OTHER

collaborator

Kyung Hee University Hospital

OTHER

collaborator

Gachon University Gil Medical Center

OTHER

collaborator

Kangbuk Samsung Hospital

OTHER

collaborator

Kyungpook National University Hospital

OTHER

lead

Asan Medical Center

OTHER